Genetic variant of CCND1: Association with HPV-mediated cervical cancer in Indian population

Biomarkers

Volumn 14, Issue 4, 2009, Pages 219-225

  Thakur, Nisha ^a   Hussain, Showket ^a   Kohaar, Indu ^a   Tabassum, Rubina ^b   Nasare, Vilas ^a   Tiwari, Pratibha ^a   Batra, Swaraj ^c   Bhambhani, Suresh ^d   Das, Bhudev C ^a   Basir, Seemi Farhat ^e   Bharadwaj, Dwaipayan ^b   Bharadwaj, Mausumi ^a  

^a Institute of Cytology and Preventive Oncology ICMR   (India)

^b CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

^c LNJP Hospital   (India)

^d Institute of Cytology and Preventive Oncology (ICMR)   (India)

^e JAMIA MILLIA ISLAMIA CENTRAL UNIVERSITY   (India)

Author keywords

Cervical cancer; Cyclin D1; G1722C; G870A; Human papillomavirus; Single nucleotide polymorphism

Indexed keywords

ADULT; ALLELE; ARTICLE; CCND1 GENE; CONTROLLED STUDY; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; INDIA; MAJOR CLINICAL STUDY; NONHUMAN; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; UTERINE CERVIX CANCER; WART VIRUS; GENE LINKAGE DISEQUILIBRIUM; GENETIC PREDISPOSITION; GENETICS; HUMAN PAPILLOMAVIRUS TYPE 16; MIDDLE AGED; UTERINE CERVIX TUMOR; VIROLOGY;

HUMAN PAPILLOMAVIRUS;

CCND1 PROTEIN, HUMAN; CYCLIN D1;

ADULT; CYCLIN D1; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMAN PAPILLOMAVIRUS 16; HUMANS; INDIA; LINKAGE DISEQUILIBRIUM; MIDDLE AGED; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; UTERINE CERVICAL NEOPLASMS;

EID: 68549137888     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.1080/13547500902825274     Document Type: Article

References (27)

1. Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J. (1995). Alternate splicing produces a novel cyclin D1 transcript. Oncogene 11:1005-1011
2. Cohen J. (2005). Public health. High hopes and dilemmas for a cervical cancer vaccine. Science 308:618-621
3. Catarino R, Matos A, Pinto D et al. (2005). Increased risk of cervical cancer associated with cyclin D1 gene A870G polymorphism. Cancer Genet Cytogenet 160:49-54. (Pubitemid 40798136)
4. Das BC, Hussain S, Nasare V, Bharadwaj M. (2008). Prospects and prejudices of human papillomavirus vaccines in India. Vaccine 26:2669-2679
5. Dyson N, Howley PM, Munger K, Harlow E. (1989). The human papillomavirus- 16 E7 oncoprotein is able to bind the retinoblastoma gene product. Science 243:934-937 (Pubitemid 19066153)
6. Franceschi S, Rajkumar T, Vaccarella S et al. (2003). Human papillomaviruses and risk factors for cervical cancer in Chennai, India: A case-control study. Int J Cancer 107:127-133
7. Gissmann L, Pfister H, Zur Hausen H. (1977). Human papillomaviruses (HPVs): Characterization of four different isolates. Virology 76:569-580
8. Grieu F, Malaney S, Ward R, Joseph D, Iacopetta B. (2003). Lack of association between CCND1 G870A polymorphism and the risk of breast and colorectal cancers. Anticancer Res 23:4257-4259
9. Haverkos H, Rohrer M, Pickworth W. (2000). The cause of invasive cervical cancer could be multifactorial. Biomed Pharmacother 54:54-59
10. Heighway J. (1991). Hae III Polymorphism within 3'untranslated region of PRAD1. Nucleic Acid Res 19:5451.
11. Holley SL, Parkes G, Matthias C et al. (2001). Cyclin D1 polymorphism and expression in patients with Squamous cell carcinoma of the head and neck. Am J Pathol 159:1917-1924
12. Jeon YT, Kim JW, Song JH et al. (2005). Cyclin D1 G870A polymorphism and squamous cell carcinoma of the uterine cervix in Korean women. Cancer Lett 223:259-263
13. Kang S, Kim JW, Park NH, Song YS, Kang SB, Lee HP. (2005). Cyclin D1 polymorphism and the risk of endometrial cancer. Gynecol Oncol 97:431-435
14. Kaur S, Sobti RC, Kaur P, Gupta I, Jain V. (2008). Cyclin D1 (G870A) polymorphism and risk of cervix cancer: A case control study in north Indian Population. Mol Cell Biochem 315:151-157
15. Kohaar I, Thakur N, Salhan S et al. (2007). TNF?-308G/A polymorphism as a risk factor for HPV associated cervical cancer in Indian population. Cell Oncol 29:249-256
16. Koike H, Suzuki K, Satoh T et al. (2003). Cyclin D1 gene polymorphism and familial prostate cancer: Fhe AA genotype of A870G polymorphism is associated with prostate cancer risk in men aged 70 years or older and metastatic stage. Anticancer Res 23:4947-4951
17. Kong S, Amos CI, Luthra R, Lynch PM, Levin B, Frazer ML. (2000). Effects of cyclin D1 polymorphism on age of hereditary nonpolyposis colorectal cancer. Cancer Res 60:249-252
18. Manos MM, Ting Y, Wright DK, Lewis AJ, Broker TR, Wolinski SM. (1989). Use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cells 7:209-214
19. Motokura T, Bloom T, Kim HG et al. (1991). A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature 350:512-515
20. Saiki RK, Gelfand DH, Stoffel S et al. (1988). Primer-directed amplification of DNA with a thermostable DNA polymerase. Science 239:487-491
21. Sambrook J, Fritsh EF, Maniatis T. (1989). Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press. p. 916-919.
22. Sathyan, KM, Nalinakumari, KR, Abraham, T, Kannan, S. (2005). Influence of single nucleotide polymorphism in H-Ras and Cyclin D1 gene on oral cancer susceptibility. Oral Oncol 42:607-613
23. Sherr CJ. 1996. Cancer cell cycles. Science 274:1672-1677
24. Trottier H, Franco EL. (2006). Human papillomavirus and cervical cancer: burden of illness and basis for prevention. Am J Manag Care 12:S462-72.
25. Wang L, Habuchi T, Takahashi T et al. (2002). Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis 23:257-264 (Pubitemid 34224000)
26. Zheng Y, Shen H, Sturgis EM et al. (2001). Cyclin D1 polymorphism and risk for Squamous cell carcinoma of the head and neck: A case-control study. Carcinogenesis 22:1195-1199 (Pubitemid 32737335)
27. zur Hausen H. (2000). Papillomaviruses and cancer: From basic studies to clinical application. Nat Rev Cancer 2:342-350